Iron homeostasis and infIammatory biomarker analysis in patients with type 1 gaucher disease

Blood Cells, Molecules, and Diseases

Volumn 53, Issue 4, 2014, Pages 171-175

  Medrano Engay, B ^a,b   Irun, P ^b,c,d   Gervas Arruga, J ^a,b,c   Andrade Campos, M ^a,b   Andreu, V ^a,b   Alfonso, P ^a,b,c   Pocovi, M ^b,c,d   Giraldo, P ^a,b,c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Chelator; Hepcidine; Inflammatory cytokines; Iron overload; Type 1 Gaucher disease

Indexed keywords

BIOLOGICAL MARKER; CCL18 CHEMOKINE; CHEMOKINE; CHITOTRIOSIDASE; DEFERASIROX; DEFEROXAMINE; FERRITIN; HEPCIDIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; IRON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; BETA N ACETYLHEXOSAMINIDASE; CYTOKINE; HAMP PROTEIN, HUMAN; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; FERRITIN BLOOD LEVEL; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; HUMAN; HYPERFERRITINEMIA; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; BLOOD; COMPLICATION; FOLLOW UP; HOMEOSTASIS; INFLAMMATION; MACROPHAGE; METABOLISM; PATHOLOGY;

ADULT; AGED; BENZOATES; BIOLOGICAL MARKERS; CYTOKINES; DEFEROXAMINE; FEMALE; FERRITINS; FOLLOW-UP STUDIES; GAUCHER DISEASE; HEPCIDINS; HEXOSAMINIDASES; HOMEOSTASIS; HUMANS; INFLAMMATION; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; QUALITY OF LIFE; TRIAZOLES;

EID: 84908116724     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.07.007     Document Type: Article

References (21)

1. Brady R.O. Gaucher's disease: past, present and future. Baillieres Clin. Haematol. 1997, 10(4):621-634.
2. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol. Genet. Metab. 2004, 83(1-2):6-15.
3. Aerts J.M., Hollak C.E. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin. Haematol. 1997, 10(4):691-709.
4. Papanikolaou G., Pantopoulos K. Iron metabolism and toxicity. Toxicol. Appl. Pharmacol. 2005, 202(2):199-211.
5. Hellström-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr. Hematol. Rep. 2003, 2(2):122-129.
6. Majhail N.S., Lazarus H.M., Burns L.J. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant. 2008, 41(12):997-1003.
7. Lee P.L., Beutler E. Regulation of hepcidin and iron-overload disease. Annu. Rev. Pathol. 2009, 4:489-515.
8. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102(3):783-788.
9. Hughes D., et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br. J. Haematol. 2007, 138(6):676-686.
10. Rennes., U.H.o. and . http://www.radio.univ-rennes1.fr.
11. Hankins J.S., et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009, 113(20):4853-4855.
12. Giraldo P., et al. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual. Life Res. 2005, 14(2):453-462.
13. http://www.Vademecum.es.
14. Giraldo P., et al. Spanish guidelines for type 1 Gaucher's disease. Med. Clin. (Barc.) 2011, 137(Suppl. 1):55-60.
15. Cohen L.A., et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010, 116(9):1574-1584.
16. Poll L.W., et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol. Dis. 2002, 28(2):209-220.
17. Bohte A.E., et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One 2013, 8(3):e57507.
18. Boot R.G., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004, 103(1):33-39.
19. Aerts J.M., et al. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr. Suppl. 2005, 94(447):43-46. (discussion 37-8).
20. Stein P., et al. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am. J. Hematol. 2010, 85(7):472-476.
21. Camaschella C. Iron and hepcidin: a story of recycling and balance. Hematol. Am. Soc. Hematol. Educ. Program 2013, 2013:1-8.